Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 909 Carboplatin 786 Paclitaxel 741 pembrolizumab 741 Bevacizumab 715 Cisplatin 707 Gemcitabine 621 Docetaxel 583 Rituximab 558 Radiotherapy 546 Dexamethasone 510 Nivolumab 488 Doxorubicin 445 Fluorouracil 392 Capecitabine 382 Etoposide 357 Pemetrexed 336 Oxaliplatin 335 Cytarabine 334 Lenalidomide 327 Prednisone 327 Erlotinib Hydrochloride 323 fludarabine phosphate 315 Trastuzumab 305 Leucovorin 299 fludarabine 296 Vincristine 288 Bortezomib 284 Filgrastim 284 Cetuximab 275

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Tissue Array Analysis × Clear all

NCT02236546 2017-04-13

FDG-PET in Advanced Melanoma

Vanderbilt-Ingram Cancer Center

Phase NA Terminated

3 enrolled 4 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡